Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib in advanced breast cancer
NCT01677455Phase 2Completed
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Jul 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of ganetespib in HER2-positive breast cancer, triple negative breast cancer (TNBC), Estrogen receptor and progesterone receptor-positive breast cancer (ER/PR+), sponsored by Synta Pharmaceuticals Corp.. Started Jul 2012; status: completed.
02
Drugs
ganetespib
03
Conditions
HER2-positive breast cancertriple negative breast cancer (TNBC)Estrogen receptor and progesterone receptor-positive breast cancer (ER/PR+)
Beyond the preview
Go deeper on NCT01677455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01677455.